New functionality helps pharmaceutical teams identify treatment delays, care gaps, and adoption barriers while preserving patient privacy and institutional control
BEAVERTON, Ore., May 6, 2025 -- datma, a leader in federated real-world data access, today announced the launch of advanced patient journey mapping capabilities within its flagship platform, datma.FED. Designed to provide pharmaceutical companies with a clearer view of how therapies are adopted in real-world care, this new functionality enables structured, privacy-preserving analysis of patient timelines across clinical, genomic, and diagnostic data.
"Designed to provide pharmaceutical companies with a clearer view of how therapies are adopted in real-world care..."
Patient journey mapping provides real-world insights into how patients move through the healthcare system, from diagnosis to therapy initiation and beyond. It helps pharmaceutical teams identify barriers that prevent timely treatment, understand care gaps, and evaluate where variation exists in provider decision-making. By supporting privacy-preserved queries across health systems and labs, datma.FED now offers a scalable approach to understanding therapy adoption patterns at the point of care.
"This launch is an important step toward helping pharma teams understand what's happening between diagnosis and treatment, where patients drop off, how providers make decisions, and why variation exists across care settings," said Robin Edison, VP of Product at datma. "This functionality gives organizations visibility without requiring raw patient-level data to be centralized or transferred."
Turning Complex Data Into Actionable Journeys
This capability uses large language models (LLMs) that extract structured timelines from unstructured and structured data sources, including clinical notes, molecular panels, medication records, and other event data. Events are categorized, timestamped, and converted into structured sequences that represent the patient journey. These representations are then analyzed using clustering methods to identify shared treatment patterns and support comparisons across different clinical sites or patient populations.
All patient journey analysis is conducted within datma.FED's federated architecture. Data remains securely within each institution's infrastructure. Journeys are computed locally, anonymized as numerical embeddings, and analyzed in aggregate. This enables cross-site insights without requiring data transfers or compromising compliance.
With this new feature, datma.FED supports:
- Mapping of diagnostic and treatment sequences across institutions
- Identifying where patients experience delays, discontinuations, or therapy changes
- Analyzing care variation across physician networks or geographic regions
- Evaluating treatment sequencing and real-world therapy use patterns
A Foundation for Better Market Access Strategy
Patient journey mapping is available as part of datma.FED's broader federated platform, which enables structured, compliant data collaboration between health systems, laboratories, and pharmaceutical organizations. All platform capabilities are designed to align with institutional privacy requirements and governance policies.
To learn more about patient journey mapping through datma.FED, visit https://www.datma.com/s/Patient-Journey-White-Paper.pdf.
About datma
datma is a leading provider of federated Real-World Data platforms and related tools designed to unlock the value of decentralized healthcare data. datma's mission is to empower healthcare organizations, researchers, and clinicians to optimize their data assets, drive innovation, and improve patient outcomes globally. The company's flagship ecosystem, datma.FED, combines AI-driven data harmonization with federated query and workflow capabilities, enabling a secure, two-sided data marketplace. Headquartered in Oregon, the company is at the forefront of transforming how healthcare data is shared and applied by enabling secure collaboration between data custodians and data consumers. By facilitating the analysis of rich, decentralized datasets without compromising privacy, datma enables health systems and reference laboratories to create secondary revenue streams and invest in innovation, while empowering data consumers with insights that may lead to discoveries, greater access, and enhanced clinical practice. For more information, visit www.datma.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
